01
Tickets ≠ revenue
Exhibitors keep roughly 48% of a domestic ticket and about 60% internationally. A $50M domestic gross sends about $26M to the distributor. Everything after this is fought over that smaller number.
The predicate
Horror is the closest thing cinema has to a financial unicorn.
Films that are not made to theatrical standards, or that go artistic instead of commercial, are failures. Most indies still fail in the equation of spectacle, novelty, and story. Romance and horror are the exceptions. In horror, as long as the picture is scary, serves its genre, and clears the minimum threshold of publishable quality, it makes money even with rotten reviews. Bonus points for something new or especially marketable, but neither is required. The bet here is not on critics. When set at the right budget, the only bet is minimum craft: whether the people you are backing can execute the genre well enough to deliver a few scary endorphins. That is the unique contract between a horror film and its audience. Everything below rests on that one judgment. Scary stories are our oldest tradition. The great ones show us who we are.
Neil Chestnutt
Producer, Advisor, Horror Director Favorite childhood movie: Dawn of the Dead Former Head of Film & Television Development of Elizabeth Bay Productions (responsible for over $2 billion at the box office)
Independently financed · theatrical release · investor economics
Controlling the mathon an independently financed theatrical film
The thesis is unglamorous: if a film costs little and gets into theaters, it tends to make money, regardless of reviews. This is a recoupment model built for the person writing the check. Set your budget, soft money, deal type and box office, and watch every dollar drain through the waterfall, on both sides of the deal at once.
The mechanism
The distributor pays the MG for the theatrical rights. The MG clears on delivery, making the financier whole before a ticket is even sold. On a $1–5M film, it's unusual for a domestic theatrical MG not to exceed the production cost.
The evidence
28 titles, 2021 – mid-2026. Median return: 5.8x the negative cost worldwide. The dataset is not a highlight reel, it is every indie-financed horror feature that reached US theaters in that period with published figures.
The trade
The distributor is only in profit if the release works. You are usually in profit from the sale. The model shows both simultaneously.
Most current industry standards: structure and standard terms follow producer Mynette Louie's breakdown on The Town with Matthew Belloni, "The 'Obsession' Windfall and How Indie Hits Pay Out" (June 11, 2026). Box office and budget figures are reported or estimated trade numbers. Education tool, not investment advice.
01 · What happens to your money, in order
Cash in, film made, then the check that pays you back
An independently financed film does not wait on box office to repay its investors. The risk is concentrated in one stage, making it, and it is retired at the sale. Everything after the delivery check is upside.
- 1Before a frame is shot
Money in
$1–5MTypical negative costEquity writes the check, alongside soft money (tax credits, rebates) and any gap debt. On a $3M negative cost with a 25% rebate, the equity exposure is closer to $1.8M.
- 220–30 shooting days
The film gets made
Max exposureEquity at risk peaks hereThis is the only stage where you can lose money outright. Cost control is the whole strategy: a contained genre picture shot short keeps the exposure low.
- 3Festival or market, on delivery1.8xMedian published MG ÷ budget
A distributor pays a minimum guarantee for rights. On a film a buyer actually wants it is priced off the negative cost, and it lands in the collection account before a ticket is sold. This is where the capital is typically returned.
- 4Weeks 1–8 in cinemas
Theatrical release
Upside onlyOverages, once the buyer is wholeThe distributor now spends its own P&A and recoups fee → marketing → MG before anything comes back to the film. Your downside is already covered; this stage only adds.
- 5Months 3–36+0.25–0.5xOf domestic box office
PVOD, the pay-1 streamer window (Netflix, Max, Peacock), free TV and home entertainment, routinely another 25–50% of domestic box office, plus sequel and library value.
Of every deal below with a published acquisition price, the median minimum guarantee is 1.8x the negative cost , paid on delivery, ahead of the release. How the distributor then recoups its fee and marketing is section 06; it changes your upside, not your downside.
Real deals, from break-even to windfall
Published figures · 2021–2026| Film | Where the investor lands | |||||
|---|---|---|---|---|---|---|
In a Violent Nature 2024 · IFC / Shudder | $600K | service deal | — | $4.56M | 7.6x | Recouped + real overages |
Late Night with the Devil 2024 · IFC / Shudder | $2.00M | service deal | — | $15.6M | 7.8x | Recouped + real overages |
Presence 2025 · Neon | $2.00M | service deal | — | $11.1M | 5.5x | Recouped + real overages |
Together 2025 · Neon | $12.0M | $17.0M | 1.4x | $34.6M | 2.9x | Profitable on the sale, thin overages |
Talk to Me 2023 · A24 | $4.25M | service deal | — | $92.2M | 21.7x | Massive net profit |
Terrifier 3 2024 · Cineverse | $2.00M | $3.67M | 1.8x | $90.3M | 45.1x | Massive net profit |
Obsession 2026 · Focus Features | $750K | $14.0M | 18.7x | $474.8M | 633.0x | Massive net profit |
Add the ancillary tail on top of every row: the pay-1 streamer licence, PVOD and home entertainment typically bring another 25–50% of domestic box office into the collection account, months after the release has finished.
The calculator below is not a binding waterfall or investment advice. It is an approximation and a set of examples built from reported deal terms and industry norms. Every real transaction is governed by its operating agreement, which may differ in fees, recoupment order, definitions of gross receipts and territories. Use this as a directional model, not a contract.
02 · Model it · start from a real-world shape
Revision: White / Aug 21, 2026
Your assumptions
Start here: cost vs. box office
The money in
The deal
A buyer pays a minimum guarantee, funds P&A and owns the release. Your exposure is reduced the day the check clears, but you only see more after the distributor recoups its fee, its marketing and its MG.
The performance
$1.80M
Soft money covers $750K
Investor cash out
$3.92M
Capital + premium + net profit share
2.18x
Profit $2.12M
$0: MG covers it
The acquisition check covers the cash need. Modeling $40.0M WW.
Who is in profit right now
Two independent ledgers, same filmYou, the equity● in profit
$2.12M
Net · 2.18x on cash at risk
- Cash in
- $1.80M
- Cash out
- $3.92M
- Whole at
- $0 WW: the MG
Covered before release. The MG exceeded the cash need, so the box office is additional if it comes.
The distributor● in profit
$7.25M
Net · 1.40x on cash at risk
- Cash at risk
- $18.2M
- Cash recovered
- $25.4M
- Whole at
- $25.1M WW
The release worked for the buyer too, which is when overages can start reaching your waterfall.
The independent financier is often in profit from the sale, not the release. The distributor is only in profit from the release. Drag the box office slider to zero: your side can stay green whenever the MG clears your cash need, and theirs goes deep red.
Step 1: Inside the distributor
Before the film sees a dollar of backendTickets are not revenue. Exhibitors keep about half domestically and 60% overseas. What reaches the distributor then pays the distributor: fee first, marketing second, its own acquisition check third. Whatever is left is the "overage."
- Gross receipts collected by distributor$29.0M
- Distribution fee (25%)Off the top, on every dollar, forever. Never recouped against.−$7.25M
- P&A recoupment (marketing spend)Distributor spent $14.0M to open the film and takes it back before anyone else.−$14.0M
- Minimum guarantee recoupmentThe acquisition check already paid to the film gets earned back here.−$4.20M
- Overage to the filmThe film is now in real backend.$3.55M
Domestic rentals: $13.0M
International rentals: $6.00M
Ancillary windows: $10.0M
Step 2: The waterfall
Paid top to bottom, in this orderEvery dollar the film collects (the MG on delivery plus overages later) lands in a neutral collection account and drains through these tiers. A tier only fills once the tier above it is full.
- 00$7.75M
- 01−$78KNeutral third party (Fintage/FFI) receives and splits every dollar per the agreed schedule.
- 02−$310KSAG-AFTRA / WGA / DGA residuals, E&O, audit and legal reserves come before profit.
- 03−$775KThe agent who sold the film at the festival / foreign markets.
- 04Capped, recoupable sales expenses−$250KMarkets, screeners, trailers, festival costs, capped in the agreement.
- 05Senior / gap debt + interest−$504KLenders are always ahead of equity. Tax-credit and gap loans get repaid first.
- 06−$1.80MInvestors get their money back before anyone sees profit.
- 07−$360KThe standard 110–120% recoupment. Paid before net profits are declared.
- 08−$150KFees people agreed to waive to get the film made get trued up here.
- 09$1.76MThe classic 50/50 corridor between the equity side and the producer/talent pool.
- 10$1.76MSplit among producers, writer/director, cast points and (increasingly) a crew bonus pool.
Net profits declared
$3.52M
The producer/talent side of $1.76M is then split again, typically producers ~40%, writer/director ~35%, cast points ~15%, and on films like Obsession a discretionary crew bonus pool for the people who worked for scale.
03 · The evidence · 2021 – mid-2026
Every single indie-financed horror release
All 28 of them, 2021 – mid-2026. Independently financed or independently produced, the money was raised outside a studio slate and a distributor came in afterwards. Every row was re-checked against Box Office Mojo and The Numbers in August 2026, and against trade reporting, and each one now carries two separate labels: how well-sourced its budget is, and what has actually been published about whether it made money. Click any row to load it into the model above.
These are estimates unless marked otherwise. Very few independent film budgets or acquisition prices are ever formally disclosed. Where a figure was confirmed by a trade outlet or a company filing it is tagged published or trade-reported; where it comes from third-party trackers it is tagged estimate; where the people who made the film have publicly contradicted the circulating number it is tagged disputed. Grosses are the only figures here that are reliably hard, and even those move with re-releases. The “reported outcome” column is what journalists and filings have said, not what this model computes.
Titles
28
2021 – mid-2026
Median WW / budget
5.8x
Worldwide gross vs negative cost
Reported profitable
18
6 confirmed outright · 8 with no published verdict
Median theaters
2,414
Peak screen count
| Film | Yr | Reported outcome (financier) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Obsession Private equity, 20-day shoot Bought out of a festival for ~19x the negative cost, before a ticket was sold. | 2026 | Focus Features | $750K trade-reported | $14.0M | 3,400 | $262.8M | $474.8M | 633.0x | $13.3M | Profitable, confirmed Profitable on the acquisition alone, the reported $14M sale was ~19x the negative cost before release. |
Together Indie equity (Australia), Sundance sale No production budget was ever disclosed; $12M is an estimate. The sale exceeded any plausible negative cost. | 2025 | Neon | $12.0M estimate | $17.0M $17M worldwide-rights deal at Sundance (Variety, ScreenDaily, LA Times) | 2,302 | $21.3M | $34.6M | 2.9x | $5.00M | Reported profitable Financier side was made whole by the $17M sale. Neon's own position sits close to break-even theatrically ($34.6M worldwide against a $17M MG plus P&A), and no outlet has published a profit statement either way, genre press in Aug 2025 said it still needed to earn to get there. |
Bring Her Back Causeway / indie equity + Australian rebate | 2025 | A24 | $15.0M estimate | not published Sony took most international rights; price undisclosed | 2,449 | $19.3M | $39.4M | 2.6x | no published price | No published verdict No published profitability verdict. $39.4M worldwide against an unconfirmed ~$15M cost. |
The Monkey C2 Motion Picture Group equity | 2025 | Neon | $10.0M trade-reported | not published Neon co-financed and produced; no acquisition price published | 3,200 | $39.7M | $68.9M | 6.9x | no published price | Reported profitable No formal profit statement, but 6.9x the reported cost worldwide and covered throughout as a clear financial success for Neon. |
Heart Eyes Spyglass equity, Sony distributes | 2025 | Spyglass / Sony | $18.0M estimate | not published | 3,102 | $30.4M | $33.1M | 1.8x | no published price | No published verdict 1.8x cost worldwide, the thinnest margin in this set, and the highest budget of the 2025 group. No published verdict. |
Presence Self-financed, 11-day shoot | 2025 | Neon | $2.00M trade-reported | not published Neon bought worldwide rights at Sundance; Deadline confirmed no figure was disclosed | 1,750 | $6.90M | $11.1M | 5.5x | no published price | Reported profitable 5.5x the reported $2M cost worldwide. No distributor profit statement published. |
Clown in a Cornfield Indie equity + Canadian rebate | 2025 | RLJE / Shudder | $3.00M estimate | not published | 2,277 | $7.25M | $13.9M | 4.6x | no published price | No published verdict Neither a budget nor a profitability figure has been published by a trade outlet; $3M is an estimate. |
The Substance Working Title / Blacksmith equity | 2024 | Mubi | $17.5M estimate | not published Variety: pre-Cannes territory deal at a figure 'rumoured to be in the low double-figure millions', explicitly a rumour, never confirmed | 1,957 | $17.6M | $77.3M | 4.4x | no published price | Reported profitable Variety confirmed it became Mubi's biggest box-office release ever and coverage tracked it clearing its reported cost within weeks. No net-profit figure published. |
Terrifier 3 Fan-funded / Dark Age Cinema, service deal ~45x the negative cost. No studio involved at any stage. | 2024 | Cineverse | $2.00M published | $3.67M Deadline: Cineverse financed the pickup with a loan of up to $3.666M, plus roughly $500K of marketing | 2,762 | $54.0M | $90.3M | 45.1x | $1.67M | Profitable, confirmed The only company-level confirmation in this set: Cineverse's reported earnings swung to profit ($7.2M net income in the quarter, $3.2M for the year) explicitly on the back of this film. |
Longlegs C2 / Range equity, Neon P&A Budget confirmed by Neon only as a range: 'under $10M'. | 2024 | Neon | $10.0M trade-reported | not published Pre-sale/market deal with Neon; price never disclosed | 2,850 | $74.3M | $125.4M | 12.5x | no published price | Profitable, confirmed Neon confirmed the budget as 'under $10M' and that it was recouped on opening day; Neon's highest-grossing release ever, and named among 2024's biggest returns by Deadline. |
Heretic Beck/Woods + A24 co-finance | 2024 | A24 | $10.0M estimate | not published | 3,221 | $28.0M | $60.0M | 6.0x | no published price | Reported profitable Reported to have passed its ~$10M cost within its opening days; no explicit distributor profit statement. |
Immaculate Black Bear / Middle Child equity | 2024 | Neon | $9.00M estimate | not published Neon acquired US rights (Deadline/Variety); price undisclosed | 2,354 | $15.7M | $35.3M | 3.9x | no published price | No published verdict No published verdict. 3.9x an unconfirmed $9M cost. |
The Strangers: Chapter 1 Fifth Season equity, three films shot back-to-back 19% on Rotten Tomatoes and still ~5.7x the reported negative cost. | 2024 | Lionsgate | $8.50M estimate | not published | 2,856 | $35.2M | $48.2M | 5.7x | no published price | Reported profitable Covered as having doubled its cost at the worldwide box office, with sequels proceeding. The budget itself is not trade-confirmed. |
MaXXXine A24 / Motel Mojave, same indie cycle as X and Pearl Budget never confirmed; press placed the trilogy's entries under $10M each. | 2024 | A24 | $10.0M disputed | not published | 2,704 | $15.1M | $22.1M | 2.2x | no published price | Reported disappointment The weakest of the trilogy commercially and covered as a disappointment against expectations. No confirmed budget, so no reliable profit read. |
Late Night with the Devil Spooky Pictures + Australian equity | 2024 | IFC / Shudder | $2.00M estimate | not published IFC/Shudder pickup; no price published | 1,442 | $12.8M | $15.6M | 7.8x | no published price | Reported profitable Deadline: IFC's biggest opening weekend ever. Roughly 7.8x an estimated $2M cost, with no profit figure published. |
Oddity Screen Ireland + indie equity Corrected in Aug 2026: earlier drafts of this table overstated the gross. | 2024 | IFC / Shudder | $1.50M estimate | not published | 790 | $1.20M | $1.85M | 1.2x | no published price | No published verdict A small theatrical footprint and a gross close to its estimated cost, the value here sat in the Shudder deal, not the box office. |
In a Violent Nature Canadian indie equity | 2024 | IFC / Shudder | $600K trade-reported | not published Acquired as a Shudder Original pre-Sundance; no figure disclosed | 1,426 | $4.23M | $4.56M | 7.6x | no published price | Reported profitable IFC's own published budget-vs-box-office figures show roughly a 7x return on a $600K cost; second-best opening in IFC history at the time. |
Talk to Me Causeway / Screen Australia A high-seven-figure sale on a low-seven-figure budget, then real overages. | 2023 | A24 | $4.25M estimate | not published Deadline, Variety and THR all reported the Sundance acquisition in the 'high seven figures'; no exact number was ever published | 2,379 | $48.3M | $92.2M | 21.7x | no published price | Reported profitable A24's highest-grossing horror release at the time at roughly 21x its reported cost. Widely reported as highly profitable, though no net figure was published. |
Thanksgiving Spyglass equity | 2023 | Spyglass / Sony | $15.0M estimate | not published | 3,204 | $31.9M | $46.6M | 3.1x | no published price | Reported profitable No explicit profit statement, but 3.1x cost worldwide and a sequel greenlit. |
The Blackening MRC / Catchlight equity | 2023 | Lionsgate | $5.00M estimate | not published | 1,775 | $17.7M | $18.6M | 3.7x | no published price | No published verdict 3.7x an unconfirmed $5M cost, almost entirely domestic. No published verdict. |
Winnie-the-Pooh: Blood and Honey Sub-$100K indie equity, sales-agent release 3% on Rotten Tomatoes. Confirmed profitable in week one. | 2023 | Fathom / Altitude | $100K published | not published | 1,652 | $2.08M | $7.72M | 77.2x | no published price | Profitable, confirmed Variety, quoting the producers, reported the film was 'already profitable' after a single opening weekend, on a budget it confirmed as under $100K. |
Skinamarink $15K self-financed micro-budget | 2023 | IFC / Shudder | $15K published | not published Acquired by IFC Midnight/Shudder; price undisclosed | 809 | $2.05M | $2.10M | 140.0x | no published price | Profitable, confirmed Budget confirmed by Deadline at $15K against a $2M+ theatrical gross and covered as a sleeper hit. Profitable on any reading. |
Barbarian Independently financed via New Regency | 2022 | 20th Century / Regency | $4.50M trade-reported | not published | 2,890 | $40.8M | $46.2M | 10.3x | no published price | Reported profitable Reported by Vulture and others as a $4.5M independently financed film that grossed $46M, roughly 10x cost. No net figure published. |
Terrifier 2 Fan-funded / self-distributed | 2022 | Cinedigm | $250K published | not published | 1,550 | $11.2M | $15.8M | 63.2x | no published price | Profitable, confirmed Variety confirmed a budget under $250K and covered the release as an outright box-office success at roughly 60x cost. |
X A24 / Motel Mojave | 2022 | A24 | $1.00M disputed | not published | 2,920 | $11.8M | $14.7M | 14.7x | no published price | Reported profitable Reported as a strong return, but the $1M budget figure was publicly disputed by the trilogy's own producer, treat the multiple as unreliable. |
Pearl A24 / Motel Mojave, shot back-to-back with X | 2022 | A24 | $1.00M disputed | not published | 2,982 | $9.40M | $9.85M | 9.8x | no published price | No published verdict Producer Peter Phok publicly rejected the widely repeated $1M budget without giving a replacement figure, so no honest profit read is possible. |
The Unholy Ghost House Pictures equity | 2021 | Screen Gems / Sony | $10.0M estimate | not published | 2,057 | $15.5M | $30.8M | 3.1x | no published price | No published verdict 3.1x an unconfirmed cost, released mid-pandemic. No published verdict. |
Spiral: From the Book of Saw Twisted Pictures equity | 2021 | Lionsgate | $20.0M estimate | not published | 2,811 | $23.2M | $40.6M | 2.0x | no published price | Reported disappointment Deadline covered the opening as well below expectations. The highest-cost title here and the weakest return relative to it. |
The profit columns. Indie financer profit is the published acquisition price / MG minus the negative cost, what the equity sees on delivery, before a single overage. It is shown only where a price was actually published; otherwise the cell reads no published price rather than inventing one. Reported outcome is what journalists and filings said about the financier's side, not the distributor's.
The trap in the WW/budget column. A 50x box-office-to-budget ratio is not a 50x investor return, and it is only as good as the budget figure feeding it, see the disputed tags. The exhibitor split, the distribution fee, the marketing recoupment and the MG recoupment all sit in front of you. Load any row into the model above and watch where it actually stops.
04 · Reviews are not returns
Films critics hated that still made money
Every film below was panned, single-digit and low-double-digit Rotten Tomatoes scores, and every one of them out-grossed its negative cost by a wide margin. None of them were good. All of them were cheap and in theaters. That is the whole mechanism: the screen count creates the gross, the low budget decides whether the gross matters.
| Film | Yr | ||||||
|---|---|---|---|---|---|---|---|
Winnie-the-Pooh: Blood and Honey A six-figure negative cost, a 3% score, and a 52x worldwide multiple. | 2023 | 3% | $100K | 1,547 | $1.90M | $5.20M | 52x |
Slender Man | 2018 | 8% | $10.0M | 2,358 | $30.6M | $51.7M | 5x |
Fantasy Island | 2020 | 8% | $7.00M | 2,784 | $27.3M | $48.0M | 7x |
The Forest | 2016 | 10% | $10.0M | 2,451 | $26.6M | $40.3M | 4x |
Brahms: The Boy II The weakest row here, and still roughly 2x its budget. | 2020 | 11% | $10.0M | 2,151 | $12.6M | $21.1M | 2x |
Winchester | 2018 | 12% | $3.50M | 2,480 | $25.1M | $44.2M | 13x |
Prey for the Devil | 2022 | 13% | $8.00M | 2,980 | $20.8M | $47.4M | 6x |
Truth or Dare PG-13, one core location, 27x budget. | 2018 | 15% | $3.50M | 3,068 | $41.4M | $95.3M | 27x |
Tarot | 2024 | 18% | $8.00M | 3,005 | $21.6M | $45.1M | 6x |
The Bye Bye Man | 2017 | 18% | $6.60M | 2,220 | $22.4M | $30.0M | 5x |
The Strangers: Chapter 1 | 2024 | 19% | $8.50M | 2,856 | $35.3M | $47.1M | 6x |
Night Swim | 2024 | 20% | $15.0M | 3,351 | $32.4M | $55.2M | 4x |
The Grudge | 2020 | 21% | $10.0M | 2,666 | $21.2M | $49.4M | 5x |
Imaginary | 2024 | 23% | $13.0M | 3,003 | $27.6M | $44.5M | 3x |
The Nun Worst-reviewed film in its franchise. Highest-grossing film in its franchise. | 2018 | 24% | $22.0M | 3,876 | $117.5M | $366.0M | 17x |
Countdown | 2019 | 26% | $6.50M | 2,675 | $26.0M | $48.0M | 7x |
The Boy | 2016 | 30% | $10.0M | 2,671 | $35.8M | $74.1M | 7x |
Five Nights at Freddy's Day-and-date on Peacock, still the clearest proof reviews and returns are unrelated. | 2023 | 33% | $20.0M | 3,675 | $137.3M | $297.2M | 15x |
Bad reviews cost you legs, not the opening
A horror opening weekend is sold on concept, date and trailer, it is bought before any review is read. Poor word of mouth shows up in the second weekend, which is why these films front-load 45–60% of domestic into three days.
The budget is the only variable you control
You cannot control reviews, the release date, the competition or the weather. You can control the negative cost. At $1–3M, an ugly $25M domestic run is still a win; at $30M it is a catastrophe.
Genre floors the downside
Horror has a reliable, date-driven audience and it travels. That floor is why distributors will spend real P&A on a film with a 12% score, and why the cheap film gets a screen count at all.
05 · The middle of the distribution · 2016 – mid-2026
The medium outcome is the one to underwrite
Drawn from a 286-title dataset of US theatrical horror releases in the last decade, narrowed to the 41 films with reported budgets under $5M that played 1,000+ domestic theaters. These are the unremarkable ones, no Get Out, no Paranormal Activity. The median film in that cohort returned 13.1x its budget at the worldwide box office.
Films in cohort
41
Sub-$5M budget, 1,000+ theaters
Median WW / budget
13.1x
Worldwide gross vs negative cost
Median in this sample
13x
The 12 medium titles below
| Film | Yr | ||||||
|---|---|---|---|---|---|---|---|
| The Witch | 2016 | A24 | $4.00M | 2,204 | $25.1M | $40.4M | 10x |
| Blair Witch | 2016 | Lionsgate | $5.00M | 3,121 | $20.8M | $45.2M | 9x |
| Truth or Dare | 2018 | Universal | $3.50M | 3,068 | $41.4M | $95.3M | 27x |
| Winchester | 2018 | CBS Films | $3.50M | 2,480 | $25.1M | $44.2M | 13x |
| Unfriended: Dark Web | 2018 | BH Tilt | $1.00M | 1,546 | $8.90M | $16.4M | 16x |
| Ma | 2019 | Universal/Blumhouse | $5.00M | 2,808 | $45.2M | $61.2M | 12x |
| Terrifier 2 | 2022 | Cinedigm | $250K | 1,550 | $10.9M | $15.7M | 63x |
| Barbarian | 2022 | 20th Century | $4.50M | 2,340 | $40.9M | $45.5M | 10x |
| The Blackening | 2023 | Lionsgate | $5.00M | 1,750 | $17.6M | $17.9M | 4x |
| Talk to Me | 2023 | A24 | $4.50M | 2,340 | $48.3M | $92.0M | 20x |
| Late Night with the Devil | 2024 | IFC / Shudder | $2.00M | 1,034 | $10.2M | $15.6M | 8x |
| Terrifier 3 | 2024 | Cineverse | $2.00M | 2,514 | $54.3M | $90.0M | 45x |
How to read this. These are the unremarkable outcomes, the middle of the distribution, not the breakouts. What matters from the equity side is the relationship between the negative cost and the gross: at this budget level, a film that simply opens wide and performs unremarkably still produces a worldwide gross many times its cost, which is what prices the acquisition and the ancillary windows that follow.
06 · Budgets and returns, by cohort
What horror costs on average, and what the $1–5M band does differently
The average US theatrical horror film costs far more than the pictures modeled here, and returns a far smaller multiple. That gap is the entire argument for staying small.
| Cohort | ||||
|---|---|---|---|---|
$1–5M wide horror 1,000+ theaters · 2003–2026 The target band. Highest median return and the highest share clearing cost of any tier. | $3.4M | $3.8M | 16.4x | 21.8x |
All US theatrical horror 417 titles with reported budgets · 2000–2026 The genre average is dragged up in cost and down in multiple by studio-scale pictures. | $24.1M | $16.0M | 3.6x | 10.8x |
Studio-financed horror Major studio + studio genre label · 249 titles Same genre, same audience, ten times the cost, and roughly a third of the hit rate. | $33.4M | $27.0M | 3.0x | 4.2x |
Wide horror over $15M 214 titles · 1,000+ theaters Above $15M the multiple collapses toward 2–3x, which is roughly break-even after marketing. | $39.0M | $30.0M | 2.7x | 3.5x |
Average studio feature (all genres) Trade-reported norm, not dataset Add $35M+ of marketing on a typical wide studio release. A studio needs roughly 2.5x worldwide to break even theatrically; a $3M film needs a fraction of that. | ~$65M | ~$50M | ~2.5x | — |
Dataset: 433 US theatrical horror releases 2000–mid-2026, 417 with reported production budgets, compiled from published trade figures. Multiples are worldwide box office divided by reported negative cost — a gross measure, not a net return. Studio all-genre cost figures are trade-reported norms rather than dataset values.
07 · Return on cost, all of cinema
Horror is the most profitable genre in the business
Rank films by gross rather than by return and horror barely appears. Rank them by what they returned against what they cost, the only measure an investor is paid on, and the genre takes the list over: 13 of the 20 most profitable features ever made, and 13 of the 20 most profitable franchises. Horror titles are in bold.
Top 20 films by return on cost
13 of 20 are horror| # | Film | |||
|---|---|---|---|---|
| 1 | Paranormal Activity2007 | $15K | $193.4M | 12,893x |
| 2 | The Blair Witch Project1999 | $60K | $248.6M | 4,143x |
| 3 | Deep Throat1972 | $25K | $100M | 4,000x |
| 4 | Eraserhead1977 | $10K | $7.0M | 700x |
| 5 | The Gallows2015 | $100K | $43.0M | 430x |
| 6 | Open Water2003 | $130K | $54.7M | 421x |
| 7 | Super Size Me2004 | $65K | $22.2M | 342x |
| 8 | El Mariachi1992 | $7K | $2.0M | 286x |
| 9 | Mad Max1979 | $350K | $100M | 286x |
| 10 | Night of the Living Dead1968 | $114K | $30.0M | 263x |
| 11 | The Texas Chain Saw Massacre1974 | $140K | $30.9M | 221x |
| 12 | Halloween1978 | $325K | $70.0M | 215x |
| 13 | Rocky1976 | $1.1M | $225M | 205x |
| 14 | Once2007 | $150K | $23.3M | 155x |
| 15 | The Devil Inside2012 | $1.0M | $101.8M | 102x |
| 16 | Saw2004 | $1.2M | $103.9M | 87x |
| 17 | The Full Monty1997 | $3.5M | $257.9M | 74x |
| 18 | Insidious2010 | $1.5M | $99.9M | 67x |
| 19 | Get Out2017 | $4.5M | $255.5M | 57x |
| 20 | Winnie-the-Pooh: Blood and Honey2023 | $100K | $5.2M | 52x |
Top 20 franchises by return on cost
13 of 20 are horror| # | Franchise | |||
|---|---|---|---|---|
| 1 | Paranormal Activity7 films | ~$28M | $890M | 32x |
| 2 | Terrifier3 films | ~$3.3M | $100M | 30x |
| 3 | Insidious5 films | ~$47M | $730M | 16x |
| 4 | My Big Fat Greek Wedding3 films | ~$50M | $770M | 15x |
| 5 | The Purge5 films | ~$40M | $530M | 13x |
| 6 | The Conjuring Universe9 films | ~$185M | $2.3B | 12x |
| 7 | Annabelle3 films | ~$65M | $770M | 12x |
| 8 | IT2 films | ~$114M | $1.17B | 10x |
| 9 | Saw10 films | ~$110M | $1.03B | 9.4x |
| 10 | Home Alone5 films | ~$100M | $920M | 9.2x |
| 11 | Fifty Shades3 films | ~$170M | $1.3B | 7.6x |
| 12 | Halloween13 films | ~$130M | $880M | 6.8x |
| 13 | The Exorcist6 films | ~$120M | $760M | 6.3x |
| 14 | Rocky / Creed9 films | ~$300M | $1.7B | 5.7x |
| 15 | The Hangover3 films | ~$250M | $1.4B | 5.6x |
| 16 | Friday the 13th12 films | ~$85M | $470M | 5.5x |
| 17 | Despicable Me / Minions6 films | ~$1.0B | $5.3B | 5.3x |
| 18 | Scream6 films | ~$180M | $945M | 5.3x |
| 19 | Final Destination6 films | ~$180M | $940M | 5.2x |
| 20 | Star Wars12 films | ~$2.1B | $10.3B | 4.9x |
Ranked by worldwide gross divided by reported negative cost, a gross return measure that ignores marketing and distribution fees, so treat it as relative, not net. Budgets are trade-reported or estimated; franchise totals sum reported budgets and lifetime grosses including reissues. Horror titles are bolded.
08 · The distributor's side of the deal
Where a theatrical dollar goes
Every $100 of tickets splits the same way. Half never leaves the cinema. The distributor pays itself next, fee, marketing, then its own acquisition check. Only the remainder reaches your waterfall. The reason a cheap film can still work is that your money came back earlier, from the sale.
$100 of ticket salesillustrative · base case
- $48
- Cinemas
- $13
- Distributor
- $23
- Distributor
- $7
- Distributor
- $9
- Your waterfall
Profitable only after the release works
- Pays out
- MG on delivery + $10–25M of P&A
- Takes back
- 25% fee off the top, then P&A, then the MG
- Breaks even at
- roughly 3–4x the P&A in worldwide box office
Usually recoups on the delivery check
- Pays in
- Equity, net of soft money and any debt
- Takes back
- The MG lands in the collection account first
- Breaks even at
- $0 of box office when the MG > the negative cost
These two ledgers move independently, and that is the whole point. A distributor can be millions underwater on a release while the equity behind the film is already whole, because the minimum guarantee, typically 1.2x–2.0x the negative cost on a film a buyer actually wants, cleared on delivery. The box office decides how much you make; the MG decides whether you lose.
09 · The other side of the trade
What happens if it never lands theatrical?
The theatrical path is the only one with an uncapped top end. Every non-theatrical exit is a buyout: a fixed number, agreed once, with no box office, no overages and no second window. Below is the same film, at $3.00M of negative cost, $2.25M of equity after a 25% rebate, run through four non-theatrical outcomes.
Negative costEquity at risk: $2.25M
Sold to a streamer (cost-plus)
Standard non-theatrical dealThe ordinary outcome when a finished genre film sells: a flat, all-rights license at roughly cost plus 20%. Equity comes back with a thin premium, and every dollar of the film's future goes with the signature, no theatrical, no overages, no second window.
- License fee / revenue to the film
- $3.60M
- Money reaching the collection account
- $3.60M
- Back to equity
- $2.70M
- Investor multiple
- 1.20x
- Profit / (loss) on $2.25M equity
- $450K
Upside above this number: none. There is no box office to overperform, so the ceiling and the floor are the same figure.
Premium streamer, competitive bid
Good non-theatrical caseTwo buyers in the room and a cast name pushes the license toward cost plus 45%. It is still a buyout: the number is settled once, and it is the entire return the film will ever produce.
- License fee / revenue to the film
- $4.35M
- Money reaching the collection account
- $4.35M
- Back to equity
- $3.00M
- Investor multiple
- 1.33x
- Profit / (loss) on $2.25M equity
- $749K
Upside above this number: none. There is no box office to overperform, so the ceiling and the floor are the same figure.
TVOD / AVOD via an aggregator
CommonNo MG, no marketing. Revenue trickles in as small transactional and ad-share payments over years, net of the platform's cut and the aggregator's fee, normally a fraction of cost.
- License fee / revenue to the film
- $1.05M
- Money reaching the collection account
- $1.05M
- Back to equity
- $538K
- Investor multiple
- 0.24x
- Profit / (loss) on $2.25M equity
- −$1.71M
Upside above this number: none. There is no box office to overperform, so the ceiling and the floor are the same figure.
No distributor at all
The downside caseThe film screens at three festivals, gets no offer, and the rights sit on a hard drive. This is what a deliverable, genre-legible film is insurance against, and why the quality threshold matters more than the release plan.
- License fee / revenue to the film
- $0
- Money reaching the collection account
- $0
- Back to equity
- $0
- Investor multiple
- 0.00x
- Profit / (loss) on $2.25M equity
- −$2.25M
Upside above this number: none. There is no box office to overperform, so the ceiling and the floor are the same figure.
No P&A means no discovery
A streamer buyout comes with an algorithm slot, not a campaign. Nobody outside the platform ever learns the film exists, which kills the library value that pays out over the following decade.
The buyout caps the deal permanently
All-rights licenses take worldwide, all media, 10–20 years. Even if the film becomes a cult title, the equity sees nothing further, the waterfall has already emptied.
Theatrical is the price of optionality
A wide release costs the distributor $15M+ in P&A and hands the film a real gross, an ancillary tail and sequel rights. It is the only path where a cheap film can return 5x or 50x instead of 1.0x.
10 · Reference
The ten things that decide your return
Every standard indie path (festival acquisition, presale/foreign-sales, distribution services, or a straight streamer buyout) runs through some version of this order.
02
It comes off the top of every dollar, in perpetuity: 25–35% on an acquisition, 10–20% on a distribution-services deal. It is never repaid to the film and it never stops.
03
P&A is senior to you
Opening a horror film wide costs $15–45M in marketing. On an acquisition the distributor fronts it and recoups it before overages; on a services deal the film funds it, usually with money that sits ahead of your equity. Marketing money is the most common reason a 'hit' produces no backend.
04
The MG is the real safety net
The minimum guarantee is paid on delivery and lands in the collection account whatever happens at the box office. For most indie investors the acquisition price, not the gross, is the return. If the MG exceeds your equity plus fees, you are whole on day one.
05
A collection account manager (Fintage, FFI) receives every dollar and pays the schedule mechanically, taking ~1%. This is what stops a distributor or producer from deciding the order themselves.
06
Off-the-top expenses come before capital
Sales agent commission (10–20%), capped market and delivery expenses, guild residuals, E&O insurance, audit and legal reserves. Budget 5–12% of collections vanishing here.
07
Tax-credit bridge loans and gap loans get principal plus 8–20% interest before equity sees a cent. Using more debt raises your multiple if the film works and wipes you out faster if it doesn't.
08
Standard terms are 110–120% recoupment: your capital returned, then a 10–20% premium, before net profits legally exist. Some deals give equity a pro-rata 'corridor' from first dollar instead, better for you, harder to get.
09
The director, cast and producers who worked below scale to make the budget close get their waived fees here, after your premium, before net profits.
10
The market standard is a 50/50 corridor: half to the equity side pro rata, half to a producer pool split among producers, the writer/director, cast points and increasingly a crew bonus pool.
10 · Reference · expenses
How the expenses actually work
Two different kinds of money get taken out: fees (a percentage of everything, forever) and recoupable expenses (a fixed pot that gets paid back once, then stops). Fees are the ones that quietly cap your upside.
| Layer | Typical size | Who takes it | Why it matters |
|---|---|---|---|
| ~48% domestic / ~60% intl | Theaters | Taken before the distributor sees anything. | |
| 25–35% (10–20% services) | Distributor | Off the top of gross receipts, never recouped against. | |
| $15–45M wide release | Distributor or film | Fully recoupable, senior to equity. | |
| = acquisition price | Distributor | Earns back the check it already paid the film. | |
| Collection manager | ~1% | CAMA | Fee on everything that passes through. |
| 3–8% | Guilds, insurers, lawyers | Contractual, non-negotiable. | |
| 10–20% + capped costs | Sales agent | Markets, festivals, deliverables. | |
| principal + 8–20% | Lenders | Gap and tax-credit bridge loans. |
10 · Reference · paths to market
The four standard paths to market
Finish the film on equity, premiere it, sell worldwide rights for an MG. Investor risk is resolved at the sale. Upside is capped by the distributor's fee + P&A + MG recoupment, so overages usually require a 4–6x-P&A gross.
A sales agent licenses territories before or during production; those contracts are discounted into a gap loan that helps fund the budget. Safer budget close, but the sales agent's commission and expenses sit above your capital.
You keep ownership and pay a 10–20% fee, but you fund P&A. Best multiple if the film opens; the fastest way to lose more than the negative cost if it doesn't.
A platform pays cost-plus (often 110–125% of budget) for all rights. Clean, quick, no waterfall past your premium, and no chance of an Obsession outcome.
11 · Data transparency
Every number here is checkable, and the whole dataset is downloadable.
Sources. Grosses and theater counts are taken from Box Office Mojo and The Numbers, last checked August 2026. Budgets, acquisition prices and profitability statements come from Deadline, Variety, The Hollywood Reporter, ScreenDaily and, where they exist, company filings and earnings calls. Deal structure and standard terms follow published producer interviews.
Published versus estimated. Very few independent budgets or acquisition prices are ever formally disclosed. Each row in the dataset carries its own sourcing flag, published, trade-reported, estimate or disputed, and a separate flag for what was actually reported about profitability, which is a different question from what this model computes. Of 28 titles, 10 carry a published or trade-reported negative cost; the rest are estimates and are labeled as such. Where a producer has publicly disputed a widely repeated budget, the figure is flagged rather than quietly used.
What is modeled, not reported. Rental splits (50% domestic, 40% international), P&A assumptions, ancillary multiples, screen-only net and every waterfall output are models, not disclosures. No distributor publishes its net. Assumptions are stated next to each table so you can substitute your own.
Corrections. Figures get revised as reissues, international runs and later reporting land. Where a number in an earlier version of this page was wrong, the correction is noted on the row rather than erased. Nothing here is a binding waterfall, an offer, or investment advice.
The full data set
Every table in this tool, with its sourcing columns intact. Download as spreadsheet-ready CSV, or browse it all on one page.
- Indie-financed horror theatrical releases (28 rows)
- Badly reviewed films that still returned capital (18 rows)
- The medium middle (sub-$5M wide releases) (12 rows)
- Budget cohort benchmarks (5 rows)
- Top 20 films by return on negative cost (20 rows)
- Top 20 franchises by return on negative cost (20 rows)
- US theatrical horror releases 2000–2026 (433 rows)CSV
- US theatrical horror $1–5M wide cohort (58 rows)CSV
12 · In closing
That's the end of the page. Thank you for interacting with it.
What I hope this data articulates is that across every theatrical horror release of the last 26 years, an independently financed $1–5M horror film, made to theatrical release standard, is the greatest path towards financial success. More than that, it allows the most creativity, the satisfaction of the audience, the building of the genre, the opportunity film was built on.
So let us move away from starting every picture as a $100M+ IP gamble. I have done plenty of those. This is the hardest margin-shift era film has been through, and at the same time the best moment for horror, for independent financing, and for the ability to impact culture and grow into something greater. Dip a toe in with a horror film, or with a slate to distribute the risk.
Please reach out to discuss. Contact Neil Chestnutt
Thank you kindly,
Maximum best,
Neil